From Sugar Addiction to a New Lease on Life: A Transformative Journey with Weight Loss Medication
For years, Danielle Tanner’s mornings began with a ritual fuelled by sugar. Once her children were safely at school, the 41-year-old from Wirral, Merseyside, would indulge in a significant portion of her daily chocolate intake, a habit that continued until bedtime. At her heaviest, weighing 16st 6lb (approximately 105kg) and wearing a size 20, her diet comprised at least 15 chocolate bars daily. Her routine involved consuming eight Orange Club and two Twix bars after the school run, followed by four Toffee Crisps after lunch, another chocolate bar post-dinner, and a box of Maltesers before bed. If she was working, she would consume four more chocolate bars on her commute home.
The turning point came when a doctor’s warning about her morbidly obese state spurred her into action. This led to a year-long transformation that saw her break free from her sugar addiction and lose an impressive seven stone (approximately 44kg).
In January 2025, Ms. Tanner was enrolled in a clinical trial for Mounjaro, a weight loss medication. The effects were almost immediate. “The first day, my head was quiet,” she recalled. “I had a salad, trying to be healthy, and I just couldn’t finish it. I hardly snacked; the desire just left my body. I didn’t change my diet, just shrunk my portion sizes – that’s why it worked so well.”
Fifteen months later, Ms. Tanner’s transformation is remarkable. She now weighs just 9st 10lb (approximately 62kg) and has swapped her oversized clothing for a size 10. Beyond the physical changes, she reports feeling significantly younger. “Since losing weight, people tell me I look 10 years younger. I actually feel it too – I’m 41, but I feel 31.”
By September 2025, she had already lost six stone (approximately 38kg), reaching 10st 6lb (approximately 67kg), a weight lighter than on her wedding day. Upon the program’s conclusion in January 2026, she had shed a total of 6st 10lb (approximately 43kg), reduced her body measurements by 56 inches, dropped from a size 20 to a size 10, and lowered her BMI from 42.1 to 24.9.
The weight loss unlocked a new level of activity in her life. Ms. Tanner embraced a variety of physical pursuits, including walking, cycling, swimming, indoor climbing, and even conquering a Ninja Warrior course. She later transitioned to Wegovy due to a price increase and has now been off injections for three weeks. Subsequent health checks indicate normal cholesterol levels and overall improved well-being.
The medication not only facilitated weight loss but also instilled a sense of moderation, which has now become ingrained in her lifestyle. “If I want chocolate, I have one bar. Pizza? A couple of slices, not the whole thing,” she explained.
Understanding the Mechanism of GLP-1 Agonists
Mounjaro belongs to a class of drugs known as GLP-1 receptor agonists (glucagon-like peptide-1). These medications mimic the action of the GLP-1 hormone, which plays a crucial role in regulating blood sugar levels and suppressing appetite after meals.
Beyond their impact on appetite and food choices during mealtimes, users have reported that these drugs influence the brain’s reward centre. This effect is believed to be a key factor in their ability to help individuals turn away from previous vices, such as excessive alcohol consumption or the overindulgence in sweets like chocolate.
Concerns about “relapse” and weight regain after discontinuing these injections are understandable, particularly given the cost of private prescriptions, which can range from £200 to £300 per month depending on the dosage. However, Ms. Tanner remains optimistic. “People worry you’ll put the weight back on when you stop the injections. You won’t – as long as you don’t go back to old habits,” she asserted. She also advocates for destigmatizing the use of medication to treat obesity, stating, “Using medication to help obese people shouldn’t have a stigma. Is it cheating? Absolutely not.”
A History of Binge Eating and the Quest for Comfort
Ms. Tanner’s struggles with food began at the age of 18, following the birth of her first child, Angel, now 23. Financial pressures and the desire for independence contributed to binge eating behaviours. After the birth of her son, Dexter, now nine, food became a primary source of comfort. She would often match her husband Ben’s large portions and bring home multiple chocolate bars or bags of crisps, driven by a lack of motivation.
She attempted to manage her weight through programs like Slimming World, achieving some initial success by losing a couple of stone. However, she found cooking challenging and often resorted to simple meals like beans and jacket potatoes. The closure of her local Slimming World group further diminished her motivation.
Ms. Tanner likens her intense craving for chocolate to an addiction. “I was like an alcoholic, but my ‘alcohol’ was chocolate,” she described. “It was a dopamine rush, and I just couldn’t stop. I needed that little monster in my head to shut up. It hasn’t just been a physical change, it’s also a mental one.”
To commemorate her significant weight loss, Ms. Tanner and her husband recreated their wedding photos. “My dress fit perfectly and laced up tighter than the first time around,” she shared. Her husband’s happiness, she noted, stems not just from her appearance but from her overall well-being. “My motivation is back, my laziness gone. I make sure I get my 10,000 steps every day. It’s like hitting a reset button.”
Prescribing Practices and the Wider Health Landscape
Under current official guidelines, Mounjaro is recommended for NHS prescription only for patients with a Body Mass Index (BMI) exceeding 40, coupled with weight-related health conditions such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Despite these guidelines, a significant number of individuals are believed to be obtaining these medications through private prescriptions.
In 2024, health authorities announced plans to provide Mounjaro to millions of obese patients through the NHS over a phased 12-year rollout, acknowledging its potential to help individuals shed up to a fifth of their body weight. The economic burden of weight-related illnesses is substantial, costing the UK an estimated £74 billion annually. Overweight and obese individuals face a heightened risk of serious health issues, including heart disease, cancer, and type 2 diabetes. Statistics reveal that two in three Britons are classified as overweight or obese, with the average weight of individuals now approximately one stone (around 6.4kg) higher than three decades ago.
